IR & Research Intelligence, Sessa Investment Research

Sessa Investment Research

IR & Research Intelligence

Sponsored research focusing on Japanese small cap.

Equity Bottom-Up

D.Western Therapeutics Institute Inc. / Equity Bottom-Up

D.Western Therapeutics Institute Inc. (4576 JP)

<ul><li>D. Western Therapeutics Institute, Inc. (DWTI, hereafter “the Company”) announced its H1 FY2026/12 results after market close on August 13, 2026.</li><li>Net sales came to JPY 33 mn (-80.9% YoY). In terms of costs, the Company recorded SG&amp;A expenses of JPY 346 mn (- 25.5% YoY), including R&amp;D expenses of JPY 217 mn (-31.7% YoY).</li><li>As a result, the Company recorded an operating loss of JPY 312 mn (loss of JPY 309 mn a year earlier), an ordinary loss of JPY 322 mn (loss of JPY 316 mn), and a net loss attributable to owners of parent (hereafter, net loss) of JPY 323 mn (loss of JPY 316 mn).</li></ul>

D. Western Therapeutics Institute, Inc. (DWTI, hereafter “the Company”) announced its H1 FY2026/12 results after market close on August 13, 2026.Net sales came to JPY 33 mn (-80.9% YoY). In terms of costs, the Company recorded SG&amp;A expenses of JPY 346 mn (- 25.5% YoY), including R&amp;D expenses of JPY 217 mn (-31.7% YoY).As a result, the Company recorded an operating loss of JPY 312 mn (loss of JPY 309 mn a year earlier), an ordinary loss of JPY 322 mn (loss of JPY 316 mn), and a net loss attributable to owners of parent (hereafter, net loss) of JPY 323 mn (loss of JPY 316 mn).

D. Western Therapeutics Institute (4576 JP) - August 20, 2026

<ul>
<li>D. Western Therapeutics Institute, Inc. (DWTI, hereafter the Company) announced its H1 FY2026/12 results after market close on August 13, 2026.</li>
<li>For TissueBlue , the Company and licensee DORC are currently discussing detailed terms and conditions for extending their agreement in the US, where the patent remains in force.</li>
<li>SIR believes that if the planned product launches proceed on schedule, expectations for the Company will rise further and be reflected in its share price.</li>
</ul>


D. Western Therapeutics Institute, Inc. (DWTI, hereafter the Company) announced its H1 FY2026/12 results after market close on August 13, 2026.
For TissueBlue , the Company and licensee DORC are currently discussing detailed terms and conditions for extending their agreement in the US, where the patent remains in force.
SIR believes that if the planned product launches proceed on schedule, expectations for the Company will rise further and be reflected in its share price.


D. Western Therapeutics Institute | 4576 FY2026/12 Q2 Follow-Up

<ul><li>In Q1 FY2026/12, D. Western Therapeutics Institute, Inc. (DWTI, hereinafter“the Company”) reported net sales of JPY 15 mn (-84.4% YoY).</li><li>In terms of costs, the Company posted SG&amp;A expenses of JPY 182 mn (-20.2% YoY), including R&amp;D expenses of JPY 117 mn (-17.5% YoY).</li><li>As a result, the Company recorded an operating loss of JPY 167 mn (loss of JPY 142 mn a year earlier), an ordinary loss of JPY 170 mn (loss of JPY 149 mn), and net loss attributable to owners of parent of JPY 170 mn (loss of JPY 150 mn).</li></ul>

In Q1 FY2026/12, D. Western Therapeutics Institute, Inc. (DWTI, hereinafter“the Company”) reported net sales of JPY 15 mn (-84.4% YoY).In terms of costs, the Company posted SG&amp;A expenses of JPY 182 mn (-20.2% YoY), including R&amp;D expenses of JPY 117 mn (-17.5% YoY).As a result, the Company recorded an operating loss of JPY 167 mn (loss of JPY 142 mn a year earlier), an ordinary loss of JPY 170 mn (loss of JPY 149 mn), and net loss attributable to owners of parent of JPY 170 mn (loss of JPY 150 mn).

Q1 Follow-Up: D. Western Therapeutics Institute (DWTI) (4576 JP) - May 26, 2026

<ul><li>D. Western Therapeutics Institute, Inc. (abbreviation: DWTI, hereinafter “the Company”) is a drug discovery bio-venture spun out from Mie University, focused on developing treatments for ophthalmic diseases.</li><li>Since its founding under the corporate philosophy of bringing “Innovative New Drugs to the World from Japan,” the DWTI Group has engaged in the research and development of drug candidates based on proprietary scientific technology derived from its research into protein kinase inhibitor development.</li><li>The Company has already launched four products and is one of the few drug discovery ventures in Japan with a track record of commercial launches.</li></ul>

D. Western Therapeutics Institute, Inc. (abbreviation: DWTI, hereinafter “the Company”) is a drug discovery bio-venture spun out from Mie University, focused on developing treatments for ophthalmic diseases.Since its founding under the corporate philosophy of bringing “Innovative New Drugs to the World from Japan,” the DWTI Group has engaged in the research and development of drug candidates based on proprietary scientific technology derived from its research into protein kinase inhibitor development.The Company has already launched four products and is one of the few drug discovery ventures in Japan with a track record of commercial launches.

Full Report - D. Western Therapeutics Institute (DWTI) (4576 JP)

<ul><li>On March 25, 2026, D. Western Therapeutics Institute, Inc. (DWTI, the Company) announced a capital and business alliance with Senju Pharmaceutical Co., Ltd., a company with strengths in the ophthalmology field.</li><li>As part of this alliance, the Company will conduct a third-party allotment of new shares to Senju Pharmaceutical (scheduled for April 10), raising JPY 199.9 mn.</li><li>The funds raised will be used to advance the development of H-1337, a glaucoma treatment currently under development by the Company, in Japan (specifically, as preparatory funds for additional non-clinical trials in Japan).</li></ul>

On March 25, 2026, D. Western Therapeutics Institute, Inc. (DWTI, the Company) announced a capital and business alliance with Senju Pharmaceutical Co., Ltd., a company with strengths in the ophthalmology field.As part of this alliance, the Company will conduct a third-party allotment of new shares to Senju Pharmaceutical (scheduled for April 10), raising JPY 199.9 mn.The funds raised will be used to advance the development of H-1337, a glaucoma treatment currently under development by the Company, in Japan (specifically, as preparatory funds for additional non-clinical trials in Japan).

D. Western Therapeutics Institute (4576 JP) - March 26, 2026

Japan

D.Western Therapeutics Institute Inc.(DWTI) is a biotechnology (bio-venture) company that focuses on development of new drugs. The Company's focus is on protein kinase inhibitors. DWTI discovers and develops several drugs, such as antiglaucoma, antihypertensive, neuroprotective, antithrombogenic, antiatherosclerosis and anticancer.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

D.Western Therapeutics Institute Inc. (4576 JP)

D. Western Therapeutics Institute (4576 JP) - August 20, 2026

D. Western Therapeutics Institute, Inc. (DWTI, hereafter “the Company”) announced its H1 FY2026/12 results after market close on August 13, 2026.

Sessa Investment Research

D. Western Therapeutics Institute | 4576 FY2026/12 Q2 Follow-Up

D. Western Therapeutics Institute, Inc. (DWTI, hereafter the Company) announced its H1 FY2026/12 results after market close on August 13,...

Sessa Investment Research

Q1 Follow-Up: D. Western Therapeutics Institute (DWTI) (4576 JP) - May 26, 2026

In Q1 FY2026/12, D. Western Therapeutics Institute, Inc. (DWTI, hereinafter“the Company”) reported net sales of JPY 15 mn (-84.4% YoY).

Sessa Investment Research

Full Report - D. Western Therapeutics Institute (DWTI) (4576 JP)

The Company has already launched four products and is one of the few drug discovery ventures in Japan with a track record of commercial launches.

Sessa Investment Research

D. Western Therapeutics Institute (4576 JP) - March 26, 2026

As part of this alliance, the Company will conduct a third-party allotment of new shares to Senju Pharmaceutical (scheduled for April 10), raising...

Sessa Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)